Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5528621 | Molecular Oncology | 2016 | 12 Pages |
Abstract
Many prognostic signatures for NB are confounded by MYCN amplification and fail to predict outcome for the subset of high-risk patients with MYCN amplification. We report a MYCN module signature that is associated with distinct patient outcomes, and predicts candidate therapeutic targets in DNA repair pathways, including PARP1 in MYCN-amplified NB.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Robin M. Hallett, Alex B.K. Seong, David R. Kaplan, Meredith S. Irwin,